[House Report 108-231]
[From the U.S. Government Publishing Office]



108th Congress                                                   Report
 1st Session          HOUSE OF REPRESENTATIVES                  108-231
======================================================================
 
PROVIDING FOR CONSIDERATION OF H.R. 2427, PHARMACEUTICAL MARKET ACCESS 
                              ACT OF 2003

                                _______
                                

  July 24 (legislative day of July 23), 2003.--Referred to the House 
                   Calendar and ordered to be printed

                                _______
                                

   Mr. Sessions, from the Committee on Rules, submitted the following

                              R E P O R T

                       [To accompany H. Res. 335]

    The Committee on Rules, having had under consideration 
House Resolution 335, by a nonrecord vote, report the same to 
the House with the recommendation that the resolution be 
adopted.

                SUMMARY OF PROVISIONS OF THE RESOLUTION

    The resolution provides for consideration in the House of 
H.R. 2427, the Pharmaceutical Market Access Act of 2003, under 
a closed rule. The rule provides one hour of debate equally 
divided and controlled by the chairman and ranking minority 
member of the Committee on Energy and Commerce, or their 
designees. The rule waives all points of order against 
consideration of the bill and provides one motion to recommit.
    The rule further provides that during consideration of the 
bill, notwithstanding the operation of the previous question, 
the Chair may postpone further consideration of the bill to a 
time designated by the Speaker.

                            COMMITTEE VOTES

    Pursuant to clause 3(b) of House rule XIII the results of 
each record vote on an amendment or motion to report, together 
with the names of those voting for and against, are printed 
below:

Rules Committee record vote No. 178

    Date: July 23, 2003.
    Measure: H.R. 2427, Pharmaceutical Market Access Act of 
2003.
    Motion by: Mr. Frost.
    Summary of motion: To make in order and provide the 
appropriate waivers for the amendment offered by Representative 
Emerson which allows the Secretary of HHS to create a Canada-
only demonstration project wherein pharmacists and wholesalers 
could ``re-import'' FDA-approved prescription medications 
manufactured in FDA-approved facilities back into the U.S.
    Results: Defeated 4 to 8.
    Vote by Members: Goss--Nay; Linder--Nay; Pryce--Nay; Diaz-
Balart--Nay; Myrick--Nay; Sessions--Nay; Reynolds--Nay; Frost--
Yea; Slaughter--Yea; McGovern--Yea; Hastings (FL)--Yea; 
Dreier--Nay.

Rules Committee record vote No. 179

    Date: July 23, 2003.
    Measure: H.R. 2427, Pharmaceutical Market Access Act of 
2003.
    Motion by: Mrs. Slaughter.
    Summary of motion: To report an open rule.
    Results: Defeated 4 to 8.
    Vote by Members: Goss--Nay; Linder--Nay; Pryce--Nay; Diaz-
Balart--Nay; Myrick--Nay; Sessions--Nay; Reynolds--Nay; Frost--
Yea; Slaughter--Yea; McGovern--Yea; Hastings (FL)--Yea; 
Dreier--Nay.

Rules Committee record vote No. 180

    Date: July 23, 2003.
    Measure: H.R. 2427, Pharmaceutical Market Access Act of 
2003.
    Motion by: Mr. McGovern.
    Summary of motion: To increase the amount of general debate 
time to four hours.
    Results: Defeated 4 to 8.
    Vote by Members: Goss--Nay; Linder--Nay; Pryce--Nay; Diaz-
Balart--Nay; Myrick--Nay; Sessions--Nay; Reynolds--Nay; Frost--
Yea; Slaughter--Yea; McGovern--Yea; Hastings (FL)--Yea; 
Dreier--Nay.

Rules Committee record vote No. 181

    Date: July 23, 2003.
    Measure: H.R. 2427, Pharmaceutical Market Access Act of 
2003.
    Motion by: Mr. Hastings of Florida.
    Summary of motion: To make in order and provide the 
appropriate waivers for the amendment offered by Representative 
Deutsch which requires the FDA to place one FDA official per 
200,000 shipments (annual) of pharmaceuticals exported from 
wholesale/distributor warehouses to the U.S. These FDA 
officials will be required to keep records of daily, weekly, 
and monthly averages regarding type and quantity of drugs to be 
re-imported into the U.S.
    Results: Defeated 4 to 8.
    Vote by Members: Goss--Nay; Linder--Nay; Pryce--Nay; Diaz-
Balart--Nay; Myrick--Nay; Sessions--Nay; Reynolds--Nay; Frost--
Yea; Slaughter--Yea; McGovern--Yea; Hastings (FL)--Yea; 
Dreier--Nay.

                                
